China: DeHeng Advised On The Restructuring Of Xingda Pharmaceutical
Last Updated: 3 September 2019

On June 15, 2018, the People's Court of Haidian District of Beijing (hereinafter referred to as the Haidian Court) decided to accept the bankruptcy reorganization case of Beijing Xingda Pharmaceutical Research Co., Ltd. (Xingda Pharmaceutical). On October 11, 2018, Haidian Court appointed Beijing DeHeng Law Offices (hereinafter referred to as "DeHeng") and Reanda Certified Public Accountants (Special General Partnership) through open bidding as co-managers of the bankruptcy reorganization case of Xingda Pharmaceutical. DeHeng and Reanda formed a management team. On the DeHeng side, partner lawyer Fan Liya, head of the Bankruptcy & Restructuring Committee was responsible for the management and another partner Zhou Jie, another member of the Bankruptcy & Restructuring Committee, took charge of on-site affairs. The management team was officially stationed in Xingda Pharmaceutical to perform its duties according to the law on October 12, 2018.

The predecessor of Xingda Pharmaceutical was Beijing Xingda Science System Company, a collective ownership enterprise. It was renamed Beijing Xingda Pharmaceutical Research Co., Ltd. after the restructuring in 2014. Xingda Pharmaceutical obtained the national new drug certificate for Dicycloplatin (DCP) (Certificate No. H2012-0021) and another for Dicycloplatin Injection (Certificate No. H2012-0020) in May 2012 and undertook national key anti-cancer drug R&D projects.

Under the supervision and direction of Haidian Court, during the nine-month restructuring period, the restructuring managers input a large number of professionals to the project, who performed the due diligence according to law and carried out a large amount of complicated work efficiently, including taking over assets, investigating financial situation, reviewing creditors' rights, handling tax-related affairs, carrying out the convergence of procedures of enforcement cases under the jurisdiction of courts outside Haidian, responding to litigation and arbitration, formulating the restructuring plan, and coordinating the interests of creditors and shareholders.

Despite that Xingda Pharmaceutical had stopped operation and there was no external investor interested in the restructuring, the management team studied the company's current asset-liability status and overcame difficulties to come up with a constructive restructuring proposal: debt-for-equity swap for some creditors in full amount, and full cash payment for some other creditors; after the swap, the former will support the company's follow-up operation, and the original investors will retain part of their shareholders' equity and provide cooperation. After rounds of consultation and communication with original investors, major creditors and other stakeholders, through the unremitting efforts of the management team, the proposal was finally recognized by all parties involved. On March 15, 2019, the draft restructuring plan was submitted to Haidian Court as scheduled. On May 14 and July 2, the draft was approved with overwhelming support from the creditor voting group and the investor voting group. On July 2, 2019, the court approved the restructuring plan submitted by the co-managers and terminated the restructuring procedure for Xingda Pharmaceutical.

It marked a decisive victory for the restructuring of the company. From then on, the restructuring plan was formally executed. After the completion of the restructuring plan, all creditors will be paid off 100%.After getting rid of all its debts, Xingda Pharmaceutical is expected to resume its production and operation, restart national key anti-cancer drug R&D projects, and generate market and social benefits.

This was the first influential restructuring case accepted by Haidian Court with managers appointed through open bidding. The management team made useful explorations in how to carry out the debt-to-equity swap in the absence of investors, how to realize full payment of cash and equivalent equity for ordinary creditors, how to converge the procedures of the restructuring case with those of non-local execution cases, the influence of debt addition on the recognition of claims in the restructuring case, accounting and preferential treatment of land value-added tax of the debtor in restructuring process, and how to properly creditor's rights involved in the litigation and shares of debt-for-equity swap of the same creditor in the restructuring scheme. They came up with many original solutions and obtained good legal effect. Through restructuring, the creditors of Xingda Pharmaceutical were 100% paid off, and the main creditors were able to invest in Xingda Pharmaceutical by way of debt-for-equity swap. Original investors of the anti-cancer R&D project had their rights and interests protected by law. It became feasible for the company to resume the R&D project. During the restructuring period, the management team was highly recognized by the court, the creditors and the original investors for its professional services and all the work it had done.

In addition to Fan Liya and Zhou Jie, senior lawyer Feng Yuejia, lawyers Zhang Ning and Qiu Liqiang, and legal assistants Kang Shiwen and Cui Mengying on the DeHeng side offered assistance for the case. On the Reanda side, certified accountants Zuo Beiping, Zhou Xing, and Wang Xiaoyan contributed to the case. China Enterprise Appraisals Consultation Co., Ltd. was the appraisal agency of the case.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Press Releases from this Firm
Recent Content from this Firm
By Mo Xie
By LI Hua, Zhang Zhipan
By Tiān Xiānjěn
By Jǐng Hŕo
By Vera Gao, Zhou Meng, Jě Qiŕn
By DeHeng Law Offices
By Li Deting
By Yan Shujing
By Zheng Hongyu, Wang Huaizhi
By Xiang DAI
Tools
Print
Font Size:
Translation
Channels
 
Mondaq Free Registration
Gain access to Mondaq global archive of over 375,000 articles covering 200 countries with a personalised News Alert and automatic login on this device.
Mondaq News Alert (some suggested topics and region)
Select Topics
Registration (please scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions